

Fig. 1

FOFESD" 64E24360




Fig. 2

1. Personal information	
1.1 Name	_____
1.2 Address	_____
1.3 Telephone	_____
1.4 E-mail	_____
1.5 Date of birth	_____
1.6 Sex	_____
1.7 Marital status	_____
1.8 Education	_____
1.9 Occupation	_____
1.10 Other information	_____
2. Study information	
2.1 Study title	_____
2.2 Study number	_____
2.3 Study date	_____
2.4 Study location	_____
2.5 Study period	_____
2.6 Study status	_____
2.7 Study results	_____
2.8 Study conclusion	_____
2.9 Study recommendation	_____
2.10 Study evaluation	_____
2.11 Study impact	_____
2.12 Study significance	_____
2.13 Study contribution	_____
2.14 Study value	_____
2.15 Study importance	_____
2.16 Study relevance	_____
2.17 Study applicability	_____
2.18 Study feasibility	_____
2.19 Study practicality	_____
2.20 Study accessibility	_____
2.21 Study availability	_____
2.22 Study obtainability	_____
2.23 Study reachability	_____
2.24 Study contactability	_____
2.25 Study approachability	_____
2.26 Study approachability	_____
2.27 Study approachability	_____
2.28 Study approachability	_____
2.29 Study approachability	_____
2.30 Study approachability	_____
2.31 Study approachability	_____
2.32 Study approachability	_____
2.33 Study approachability	_____
2.34 Study approachability	_____
2.35 Study approachability	_____
2.36 Study approachability	_____
2.37 Study approachability	_____
2.38 Study approachability	_____
2.39 Study approachability	_____
2.40 Study approachability	_____
2.41 Study approachability	_____
2.42 Study approachability	_____
2.43 Study approachability	_____
2.44 Study approachability	_____
2.45 Study approachability	_____
2.46 Study approachability	_____
2.47 Study approachability	_____
2.48 Study approachability	_____
2.49 Study approachability	_____
2.50 Study approachability	_____
2.51 Study approachability	_____
2.52 Study approachability	_____
2.53 Study approachability	_____
2.54 Study approachability	_____
2.55 Study approachability	_____
2.56 Study approachability	_____
2.57 Study approachability	_____
2.58 Study approachability	_____
2.59 Study approachability	_____
2.60 Study approachability	_____
2.61 Study approachability	_____
2.62 Study approachability	_____
2.63 Study approachability	_____
2.64 Study approachability	_____
2.65 Study approachability	_____
2.66 Study approachability	_____
2.67 Study approachability	_____
2.68 Study approachability	_____
2.69 Study approachability	_____
2.70 Study approachability	_____
2.71 Study approachability	_____
2.72 Study approachability	_____
2.73 Study approachability	_____
2.74 Study approachability	_____
2.75 Study approachability	_____
2.76 Study approachability	_____
2.77 Study approachability	_____
2.78 Study approachability	_____
2.79 Study approachability	_____
2.80 Study approachability	_____
2.81 Study approachability	_____
2.82 Study approachability	_____
2.83 Study approachability	_____
2.84 Study approachability	_____
2.85 Study approachability	_____
2.86 Study approachability	_____
2.87 Study approachability	_____
2.88 Study approachability	_____
2.89 Study approachability	_____
2.90 Study approachability	_____
2.91 Study approachability	_____
2.92 Study approachability	_____
2.93 Study approachability	_____
2.94 Study approachability	_____
2.95 Study approachability	_____
2.96 Study approachability	_____
2.97 Study approachability	_____
2.98 Study approachability	_____
2.99 Study approachability	_____
2.100 Study approachability	_____

Fig. 3

Fig. 3




Fig. 4






Fig. 6

Fig. 7




Fig. 7A-D






Fig. 7E-H




Fig. 8



Fig. 9




Fig. 9A-D




Fig. 9E-H




Fig. 10





Fig. 11

A



B





Fig. 12



A



B





Fig. 13

A



B





Fig. 14

A



B




Fig. 15

B




Fig. 16

A




Fig. 16A




Fig. 17




Fig. 18A

The diagram illustrates the construction of the pWW1 vector. It starts with two parent plasmids: M13-WW1 (8140 bp) and pdHL7-CC49 (9423 bp). M13-WW1 contains a HindIII site (H), a NarI site (N), a BstEII site (B), a PstI site (P), and an origin of replication (ori). pdHL7-CC49 contains a HindIII site (H), a XhoI site (X), a SacI site (S), a BstEII site (B), a PstI site (P), a Cy1 site (C), a Nacl site (N), an XhoI site (X), an ori, an Amp<sup>r</sup> gene, a DHFR gene, an SV40 gene, an HCMV promoter, a V<sub>κ</sub> gene, a BamHI site (B), and a XbaI site (X). The construction involves digesting M13-WW1 with HindIII and BstEII to create a fragment with HindIII and BstEII sites. This fragment is then ligated into the pdHL7-CC49 vector, which has been digested with HindIII and BstEII, to create the pWW1 vector. The pWW1 vector contains the HCMV promoter, V<sub>κ</sub> gene, BamHI site, XbaI site, SV40 gene, DHFR gene, Amp<sup>r</sup> gene, ori, and the HindIII, XhoI, SacI, BstEII, PstI, Cy1, and Nacl sites.

Fig. 18B






Fig. 19A




Fig. 19B




Fig. 20A




Fig. 20B

The diagram illustrates the construction of the pWW3 plasmid through the following steps:

- Parental Plasmids:**
  - pCC49t-WW3 (7794 bp):** Contains a Cx gene, HCMV promoter, V $\kappa$  gene, SV40, DHFR, Amp, and ori. Restriction sites for XhoI, NruI, HindIII, SacII, BglII, BamHI, XbaI, and PstI are indicated.
  - pdHL7-CC49 (9423 bp):** Contains a Cx gene, HCMV promoter, V $\gamma$ 1 gene, Cy1 gene, PstI, SacII, NaeI, XhoI, ori, Amp, DHFR, and SV40. Restriction sites for SnaBI, XhoI, HindIII, SacII, BstEII, PstI, XbaI, BamHI, and PstI are indicated.
- Restriction Digestion:**
  - pCC49t-WW3 is digested with HindIII and XbaI to excise a fragment containing the V $\kappa$  gene and surrounding sequences.
  - pdHL7-CC49 is digested with HindIII and XbaI to excise a fragment containing the V $\gamma$ 1 gene and surrounding sequences.
- Ligation:** The two fragments are ligated to form the final pWW3 plasmid.
- Final Plasmid (pWW3, 9423 bp):** Contains the Cx gene, HCMV promoter, V $\kappa$  gene, SV40, DHFR, Amp, and ori. Restriction sites for XhoI, NruI, HindIII, SacII, BstEII, PstI, XbaI, BamHI, and PstI are indicated.

6




Fig. 21A

The diagram illustrates the construction of the pWW4 plasmid through three stages:

- M13-WW4 (7665 bp):** A circular plasmid with an origin of replication (ori) and a BamHI site. It is flanked by XbaI and EaeI sites.
- pdHL7-CC49 (9423 bp):** A circular plasmid with an origin of replication (ori), Ampicillin resistance (Amp), DHFR, SV40, HCMV, Cx, and 1VY1 regions. It is flanked by XbaI and BamHI sites.
- pWW4 (9423 bp):** The final plasmid, constructed by inserting the BamHI site from M13-WW4 into the pdHL7-CC49 plasmid. The resulting plasmid contains the ori, Amp, DHFR, SV40, HCMV, Cx, and 1VY1 regions, with the BamHI site from M13-WW4 inserted.

Restriction enzymes used for cloning are indicated at various sites: XbaI, BamHI, EaeI, XhoI, HindIII, SacII, BstEII, PstI, NaeI, and SnaBI.

Fig. 21B




Fig. 22A






Fig. 22B




Fig. 23A




Fig. 23B






Fig. 25






Fig. 26B




Fig. 26C






Fig. 26D




Fig. 27A-E




Fig. 27




Fig. 28




Fig. 29




Fig. 30




Fig. 31




Fig. 32






Fig. 33




Fig. 34




Fig. 35

Figure 1 is a line graph showing the stability of  $[^{32}\text{P}]\text{MAb}$  in different media over a 5-day period. The y-axis represents the percentage of  $[^{32}\text{P}]\text{MAb}$  remaining, ranging from 0 to 100%. The x-axis represents time in days, from 0 to 5. Four media are compared: Buffer, FBS (Fetal Bovine Serum), Human Serum, and Mouse Serum. In all media, the  $[^{32}\text{P}]\text{MAb}$  remains highly stable, with less than 5% degradation observed after 5 days.

Time (Days)	Buffer (%)	FBS (%)	Human Serum (%)	Mouse Serum (%)
0	100	100	100	100
1	100	100	98	98
2	100	100	97	97
3	100	100	96	96
4	100	100	95	95
5	100	100	94	94

Fig. 36




Fig. 37

	Upper	Core	Lower
<b>A:</b> MAb-chCC49:	EPKSCDKTHT	CPPCP	APELLGGP
MAb231:	EPRGPTIKP	CPPCKCP	APNLLGGP
MAb61.1.3:	VPRDCG	CKPCICT	VPEV

**B:** MAb-chCC49 x MAb231

```

1 EPKSCDKTHTCPP..CPAPELLGGP 23
  |||          |||  |||  |||  |||
1 EPRG.PTIKPCPPCKCPAPNLLGGP 24

```

**C:** MAb-chCC49 x MAb61.1.3

```

1 EPKSCDKTHTCPPCPAPELLGGP 23
  |||  |||  |||  |||
1 VPRDCGCKPCICTVPEV 17

```

Fig. 38




Fig. 39




Fig. 40





Fig. 41




Fig. 42

